Search Results - "Giffoni de Mello Morais Mata, Danilo"

Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review by Giffoni de Mello Morais Mata, Danilo, Chehade, Rania, Hannouf, Malek B, Raphael, Jacques, Blanchette, Phillip, Al-Humiqani, Abdullah, Ray, Monali

“…Background: The overexpression of the human epidermal growth factor receptor 2 (HER2+) accounts for 15–20% of all breast cancer phenotypes. Even after the…”
Get full text

Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review by Mata, Danilo Giffoni de Mello Morais, Amir Carmona, Carlos, Eisen, Andrea, Trudeau, Maureen

“…Background: Approximately 75% of breast cancer (BC) is associated with luminal differentiation expressing endocrine receptors (ER). For ER+ HER2− tumors,…”
Get full text

The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer-A Systematic Review and Meta-Analysis by Giffoni de Mello Morais Mata, Danilo, Rush, Mary-Beth, Smith-Uffen, Megan, Younus, Jawaid, Lohmann, Ana Elisa, Trudeau, Maureen, Morgan, Rebecca L

“…Anthracycline-taxane is the standard chemotherapy strategy for treating high-risk early breast cancer despite the potentially life-threatening adverse events…”
Get full text

Immunotherapy for older patients with cancer by Araujo Vargas, Tatianny P., Al-Humiqani, Abdullah, Giffoni De Mello Morais Mata, Danilo, Menjak, Ines B.

“…The aim of this review is to describe the clinical use and tolerability of immune checkpoint inhibitors in older adults with solid tumors, where there is an…”
Get full text

Predicting treatment toxicity in older adults with cancer by Menjak, Ines B., Giffoni de Mello Morais Mata, Danilo, Chesney, Tyler R., Haase, Kristen R.

“…To provide an overview of the recent advancements in predicting toxicity associated with cancer treatment in older patients. Various screening tools and…”
Get full text

Overall survival comparison in patients with and without brain metastases treated with osimertinib for metastatic EGFR mutation positive non-small cell lung cancer (NSCLC) by Giffoni de Mello Morais Mata, Danilo, Romero, Maria Luisa, Carmona Gonzalez, Carlos Amir, Thawer, Alia, Doherty, Mark, Menjak, Ines B.

“…Abstract only e21216 Background: With the development of Epidermal Growth factor receptor (EGFR) tyrosine kinase inhibitors such as Osimertinib, the landscape…”
Get full text

Sequencing of systemic therapies in advanced NSCLC with MET exon 14 skipping mutation: A multicenter experience by Lau, Sally C. M., Perdrizet, Kirstin, Giffoni de Mello Morais Mata, Danilo, Fung, Andrea S., Liu, Geoffrey, Bradbury, Penelope Ann, Shepherd, Frances A., Sacher, Adrian G., Sheffield, Brandon, Hwang, David, Tsao, Ming Sound, Cheng, Susanna Y., Cheema, Parneet, Leighl, Natasha B.

“…Abstract only e21123 Background: The treatment landscape for patients with metastatic non-small cell lung cancer (mNSCLC) with a MET exon 14 skipping mutation…”
Get full text

Predicting treatment toxicity in older adults with cancer by Menjak, Ines B., Giffoni de Mello Morais Mata, Danilo, Chesney, Tyler, Haase, Kristen R.

Get full text